VascVersa
1 known investors
VascVersa develops advanced cell and gene therapies to regenerate the retinal micro-vasculature and treat vision loss caused by ischaemia, such as diabetic retinopathy and age-related macular degeneration. Building on research from Queen's University Belfast, it has patented a process to extract and scale a rare vasculature-regenerating blood cell (Angicyte) and analyzes its transcriptome (AngiGenix) to develop genetic therapies.
Investors Β· 1
Frequently asked questions
- What does VascVersa do?
- VascVersa develops advanced cell and gene therapies to regenerate the retinal micro-vasculature and treat vision loss caused by ischaemia, such as diabetic retinopathy and age-related macular degeneration. Building on research from Queen's University Belfast, it has patented a process to extract and scale a rare vasculature-regenerating blood cell (Angicyte) and analyzes its transcriptome (AngiGenix) to develop genetic therapies.
- Who are VascVersa's investors?
- VascVersa's investors include Clarendon Fund Managers Ltd..